scholarly journals Modern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. Case report

2021 ◽  
Vol 23 (2) ◽  
pp. 287-291
Author(s):  
Albina S. Zhabina ◽  
Fedor V. Moiseenko ◽  
Nikita M. Volkov ◽  
Nuriniso Kh. Abduloeva ◽  
Vladimir M. Moiseenko
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
High Recurrence Rate ◽  
Complete Regression ◽  
Small Cell Lung ◽  
Standard Chemotherapy ◽  
International Trial ◽  
Extensive Stage

Extensive-stage small cell lung cancer (ES-SCLC) is characterized by an aggressive course, a high recurrence rate and fast progression. For a long time, the survival prognosis for the most patients suffering from this disease remained unfavorable. The situation changed with the appearance of chemoimmunotherapy in clinical practice. Chemotherapy based on durvalumab in comparison with the standard chemotherapy demonstrated the statistically and clinically significant increase in median overall survival in patients with previously untreated ES-SCLC in the CASPIAN international trial. This article deals with the case of the application of standard chemotherapy in combination with durvalumab as a first-line ES-SCLC therapy. The patient started receiving durvalumab therapy in June 2017 as a part of the CASPIAN international trial. In March 2021 the duration of therapy was 45 months, the patient had a complete regression of the disease.

scholarly journals Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508)

Cancer ◽  
2016 ◽  
Vol 122 (15) ◽  
pp. 2371-2378 ◽  
Author(s):  
Chandra P. Belani ◽  
Suzanne E. Dahlberg ◽  
Charles M. Rudin ◽  
Martin Fleisher ◽  
Helen X. Chen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Research ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Research Group ◽  
Small Cell ◽  
Small Cell Lung ◽  
Standard Chemotherapy ◽  
Extensive Stage

Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review

Immunotherapy ◽  
2021 ◽  
Author(s):  
Xingyu Liu ◽  
Huifang Xing ◽  
Hongbing Zhang ◽  
Hongyu Liu ◽  
Jun Chen
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Progression Free Survival ◽  
Small Cell ◽  
Small Cell Lung ◽  
Standard Chemotherapy ◽  
Free Survival ◽  
Extensive Stage

Aim: We conducted a systematic review and network meta-analysis to evaluate the efficacy of immunotherapy versus chemotherapy to treat extensive-stage small-cell lung cancer. Methods: We analyzed several eligible clinical trials using fixed or random-effects models to evaluate relative treatment effects depending on heterogeneity. Results: In the experimental group, immunotherapy showed significant improvement in overall survival (hazard ratio [HR]: 0.82; 95% CI: 0.74–0.89; I2 = 31.4%; p < 0.001) and progression-free survival (HR: 0.77; 95% CI: 0.80–0.83; I2 = 22.7%; p < 0.001). Conclusion: Immunotherapy is likely to significantly improve extensive-stage small-cell lung cancer patients' overall survival and progression-free survival compared with standard chemotherapy. Anti-PD L1 exhibited superior overall survival compared with anti-PD 1 and anti-CTLA4.

Sign in / Sign up

Export Citation Format

Share Document